News

Conference: Walters at ISPE Annual Meeting

November 5, 2020

Peter Walters will be leading the multi-product ATMP facilities for future flexibility session on Thursday, November 5th at 9:30 am.

The rapidly growing advanced therapy medicinal product (ATMP) market gives hope to people suffering from previously untreatable and rare diseases. But, to make that hope a reality, manufacturers must find a way to produce ATMPs quickly, efficiently and at scale. With companies now having a multitude of different product modes within their portfolio (mAb, cell-based therapies, viral vectors, novel technologies, etc), the need for a facility which can accommodate different process platforms is greater than ever before.

This session will present several different future-facing product types and how to provide the best possibility for an effective and efficient multi-product facility. We will discuss the science and manufacturing considerations around how to make these products compatible (under one roof), how to potentially leverage synchronicity in shared resources for each production space, and ultimately explore the design that will make this flexible facility a reality. Achieve an appropriate scale, faster speed-to-market, lower costs, and manufacturing flexibility with a multi-product ATMP facility.

The impressive session if speakers include:

Minimize downtime and maximize growth, no matter what the market holds

Edward M. Domanico 
VP, Program Director
Bayer

<and>

Peter Walters
ATMP Director
SlateXpace™

Future proofing end-to-end gene therapy solutions, from preclinical to commercial launch

Thomas Page, PhD
VP Engineering and Asset Development
FujiFilm Diosynth Biotechnologies

The vision to go bold with multi-product facilities

Charlotte Cooper Holmes
Associate Director MSAT
Bluebird Bio

ISPE Annual Conference

November 2-6, 2020